Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations
- 1 April 2001
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 53 (4) , 555-561
- https://doi.org/10.1211/0022357011775677
Abstract
Hyaluronic acid (HA), an abundant non-sulfated glycosaminoglycan component of the extracellular matrix, has applications in drug delivery, tissue engineering and as an ingredient in cosmetics. HA preparations containing high-molecular-weight polymers are also used in the treatment of inflammatory disorders such as arthritis and interstitial cystitis. Low-molecular-weight fragments derived from HA have been reported to induce pro-inflammatory cytokines such as IL-12 and TNF-α, and could therefore potentially exacerbate existing inflammation. We therefore examined the pro-inflammatory activity of HA preparations, since inflammatory reactions are known to occur following administration of HA. We tested low-molecular-weight fragments obtained from seven different HA preparations, either by sonication (≅ 3 times 105 Da) or by hyaluronidase digestion (≅ 1 times 104 Da), for the ability to induce the synthesis of IL-12 and TNF-α by human monocytic cells. We found that two of the seven HA preparations tested stimulated the synthesis of IL-12 and TNF-α by human monocytic cells. We unexpectedly found that the induction of IL-12 and TNF-α by these HA preparations was not due to their degradation to low-molecular-weight fragments, since their native high-molecular-weight forms possessed the same ability to stimulate IL-12 and TNF-α synthesis, but was due to the presence of contaminating DNA. Treatment of these two HA preparations with deoxyribonuclease I abrogated or reduced the induction of IL-12 and TNF-α. It is clear from this study that HA preparations can induce the synthesis of pro-inflammatory cytokines by monocytes. The ability of HA to act as a pro-inflammatory mediator may not, however, be related to the presence of low-molecular-weight HA fragments, but to the presence of DNA. The presence of pro-inflammatory DNA in HA preparations should be evaluated before its use, not only for the treatment of patients with inflammatory disorders, but also before many other applications.Keywords
This publication has 36 references indexed in Scilit:
- INCREASED URINARY HYALURONIC ACID AND INTERSTITIAL CYSTITISJournal of Urology, 1998
- Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44.Journal of Clinical Investigation, 1996
- CD44: one ligand, two functions.Journal of Clinical Investigation, 1996
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Cytokine regulation of human lung fibroblast hyaluronan (hyaluronic acid) production. Evidence for cytokine-regulated hyaluronan (hyaluronic acid) degradation and human lung fibroblast-derived hyaluronidase.Journal of Clinical Investigation, 1992
- Abnormal urothelial HLA-DR expression in interstitial cystitisClinical and Experimental Immunology, 1992
- Increased Luminal Release of Hyaluronan in Uninvolved Jejunum in Active Crohn’s Disease but Not in Inactive Disease or in RelativesDigestion, 1992
- Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis.Thorax, 1989
- Depolymerisation products of hyaluronic acid after exposure to oxygen-derived free radicals.Annals of the Rheumatic Diseases, 1985
- Intravesical Hyaluronic Acid in the Treatment of Refractory Interstitial CystitisPublished by Wolters Kluwer Health